Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CAN-3110 by Candel Therapeutics for Recurrent Malignant Glioma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for Recurrent Malignant Glioma. According to GlobalData,...
CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...
Aglatimagene besadenovec by Candel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
Aglatimagene besadenovec by Candel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...